ACTRIMS 2022 | MSDA validation test algorithm – the benefits to clinical practice

Ferhan Qureshi, BS, Vice President, Octave Bioscience, Menlo Park, CA, comments on what the MSDA validation test algorithm can bring to multiple sclerosis (MS) clinical practice. Mr. Qureshi states that prior to test development, market research was conducted to understand the goals of neurologists. They learned that their primary objectives were to manage patients to no evidence of disease activity (NEDA), reduce the number of relapses, and slow disease progression. This test was developed to provide a quantitative score of a patient’s disease activity – combining the MSDA test with clinical insights, and an MRI insights program to produce objective measurement tools for doctors to monitor their patients. The primary goal is to enable clinicians to provide the correct therapy, to the right patient, at the best time. This interview took place at the ATCRIMS Forum 2022 in West Palm Beach, Florida.